Nesiritide
BNP (B-type natriuretic peptide) for acute decompensated heart failure. Vasodilatory and natriuretic peptide reducing cardiac preload and afterload in severe heart failure exacerbations.
Nesiritide is recombinant human B-type natriuretic peptide (rhBNP), a 32-amino-acid polypeptide hormone containing an intramolecular disulfide bond (Cys10-Cys26) forming a cyclic structure. BNP is an endogenous hormone secreted by ventricular myocytes in response to increased volume load or wall tension, possessing multiple physiological effects including vasodilation, natriuresis/diuresis, and suppression of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system. As an intravenous agent, nesiritide is primarily used for hospitalized patients with acute decompensated heart failure (ADHF) to rapidly reduce cardiac preload and afterload and improve dyspnea.
| Parameter | Specification |
| CAS | 124584-08-3 |
| Molecular Formula | C₁₄₃H₂₄₄N₅₀O₄₂S₄ |
| Molecular Weight | 3464.04 g/mol |
| Category | Cardiovascular |
| Purity | ≥99% |
| Status | GMP-compliant, FDA-ready |
| Applications | Acute decompensated heart failure, vasodilation, natriuresis |
| CAS | 124584-08-3 |
|---|---|
| Applications | Acute Decompensated Heart Failure, HF Emergency, Vasodilation |




